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ABSTRACT
Background: Crohn’s disease and ulcerative colitis have
a complex genetic background. We assessed the risk for
both the development and severity of the disease by
combining information from genetic variants associated
with inflammatory bowel disease (IBD).
Methods: We studied 2804 patients (1684 with Crohn’s
disease and 1120 with ulcerative colitis) and 1350
controls from seven university hospitals. Details of the
phenotype were available for 1600 patients with Crohn’s
disease and for 800 with ulcerative colitis. Genetic
association for disease susceptibility was tested for the
nucleotide-binding and oligomerisation domain 2 gene
(NOD2), the IBD5 locus, the Drosophila discs large
homologue 5 and autophagy-related 16-like 1 genes
(DLG5 and ATG16L1) and the interleukin 23 receptor gene
(IL23R). Interaction analysis was performed for Crohn’s
disease using the most associated single nucleotide
polymorphism (SNP) for each locus. Odds ratios were
calculated in an ordinal regression analysis with the
number of risk alleles as an independent variable to
analyse disease development and severity.
Results: Association with Crohn’s disease was confirmed
for NOD2, IBD5, DLG5, ATG16L1 and IL23R. Patients with
Crohn’s disease carry more risk alleles than controls
(p = 3.85 6 10222). Individuals carrying an increasing
number of risk alleles have an increasing risk for Crohn’s
disease, consistent with an independent effects multi-
plicative model (trend analysis p = 4.25 6 10223).
Patients with Crohn’s disease with a more severe disease
course, operations or an age of onset below 40 years
have more risk alleles compared to non-stricturing, non-
penetrating behaviour (p = 0.0008), no operations
(p = 0.02) or age of onset above 40 years (p = 0.028).
Conclusion: Crohn’s disease is a multigenic disorder. An
increase in the number of risk alleles is associated with an
increased risk for the development of Crohn’s disease and
with a more severe disease course. Combining informa-
tion from the known common risk polymorphisms may
enable clinicians to predict the course of Crohn’s disease.
Chronic inflammatory bowel diseases (IBDs) com-
prising Crohn’s disease and ulcerative colitis are
characterised by chronic recurring inflammation of
the gastrointestinal tract. The combined preva-
lence of Crohn’s disease and ulcerative colitis is
estimated at 100/100 000 to 200/100 000 in devel-
oped countries.1 2 Concordance rates in twins and
siblings suggest that a genetic predisposition
contributes to the pathogenesis of IBD, but the
disease is complex and expected to be due to
multiple predisposing genes.3 4
In 2001 the nucleotide-binding and oligomerisa-
tion domain 2 (NOD2) gene on chromosome 16
was the first susceptibility gene identified for
IBD.5 6 Three mutations (R702W, G908R and
3020insC) are independently associated with
Crohn’s disease in Caucasian patients. More
recently, several more IBD susceptibility genes
have been identified. A widely replicated associated
locus is the IBD5 locus on chromosome 5q31–q33,
including the genes solute carrier family 22
members 4 and 5 (SLC22A4 and 25) encoding for
the organic cation transporters 1 and 2.7 8
Unfortunately, the causative IBD susceptibility
gene from this region has not yet been identified
unequivocally. In addition, refining a linkage
region previously found on chromosome 10q23
led to the identification of the Drosophila discs
large homologue 5 (DLG5) gene as a susceptibility
gene for Crohn’s disease and IBD.9 Although results
have been conflicting, a large meta-analysis
showed that carriage of the major allele of the
R30Q variant DLG5 confers a small risk for
developing Crohn’s disease in women.10 A recent
genome-wide association scan identified a coding
single nucleotide polymorphism (SNP), within the
autophagy-related 16-like 1 gene (ATG16L1) on
chromosome 2q37.1, to be strongly associated with
Crohn’s disease.11 This association has been con-
firmed in several independent cohorts.12 13 Finally, a
genome-wide association study found that genetic
variation in the interleukin 23 receptor gene
(IL23R) has a protective effect for developing
Crohn’s disease.14 This finding has been confirmed
in different study populations.13 15 In addition to
these genes several further genes have been
identified very recently by large-scale genome-wide
association studies. These include a locus on
chromosome 5p13.1, nel-like 1 precursor (NELL-1)
and the autophagy-inducing immunity-related
GTP-ase family M (IRGM) gene found by the
Wellcome Trust Case Control Consortium
(WTCCC).16–18
IBD shows extensive variation in the individual
clinical presentation and outcome, and it is
tempting to speculate that this is most likely due
to differences in the genetic susceptibility in
combination with exposure to environmental
factors, such as the commensal bacteria in the
intestine, and the intestinal immune system.1
Since many of the identified polymorphisms only
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moderately increase the risk for disease development with allelic
odds ratios (ORs) below 1.5, they have no value in predicting an
individual’s risk for disease development. However, these
common, low penetrance risk alleles may be responsible for a
large fraction of the genetic component of a complex multi-
factorial disease like IBD. Previous studies on simulated data,
and recently on data from patients with Crohn’s disease and
type 2 diabetes, have shown the possibility of combining
information from multiple risk alleles to predict the risk for
disease development.19–21
The aim of this study was to confirm IBD-associated genes in
the Dutch population and to examine the combined effect of
these genetic variants in predicting disease development. We
also studied whether an increase in the number of common risk
alleles was associated with a more severe disease course. We
analysed genetic variants in NOD2, the IBD5 locus, DLG5,
ATG16L1 and IL23R for association with IBD, Crohn’s disease,
ulcerative colitis and different subsets of Crohn’s disease and
ulcerative colitis in a large nationwide case–control study,
including well-phenotyped patients with IBD from seven
university medical centres (UMCs) in The Netherlands.
METHODS
Patients and controls
The study population consisted of 2804 patients of Caucasian
ethnicity with IBD (1684 with Crohn’s disease, and 1120 with
ulcerative colitis) and 1350 Caucasian controls from seven
UMCs in The Netherlands: Academic Medical Center,
Amsterdam (n = 772), VU University Medical Center,
Amsterdam (n = 596), University Medical Center Groningen
(n = 516), Leiden University Medical Center (n = 503), Erasmus
Medical Center, Rotterdam (n = 183), Radboud University
Nijmegen Medical Center (n = 156), and University Medical
Center Utrecht (n = 78).22–26 Controls consisted of healthy
volunteers from the UMC Utrecht (n = 784), UMC Groningen
(n = 284), UMC Leiden (n = 168) and UMC Nijmegen
(n = 114).22 24–25 There was no significant number of Jewish
patients in this cohort.
Patients were diagnosed according to accepted clinical, endo-
scopic, radiological and histological findings.1 All patients and
controls gave their informed consent and all DNA samples and
data in this study were handled anonymously. For patients with
Crohn’s disease, phenotypic details were registered according to
the Vienna classification. However, perianal disease was also
scored as an independent variable. Upper GI localisation was
scored separately and was not mutually exclusive with ileal,
colonic or ileocolonic localisation.27 For patients with ulcerative
colitis, phenotypes were described according to age of onset,
extent of disease (proctitis, left-sided or extensive), necessity of
colectomy and the occurrence of extra-intestinal manifestations:
arthtritis/arthralgia, sacroiliitis, hepatobiliary complications (eg,
primary sclerosing cholangitis (PSC)), and cutaneous or ocular
manifestations. Phenotyping was performed by the participating
gastroenterologist from each UMC by reviewing a patient’s chart
retrospectively. All participants received a detailed description of
classification rules and the details had to be filled out in a
structured form. Phenotypic details were available for 1600 of
1684 (95.0%) patients with Crohn’s disease and for 800 of 1120
(71.4%) patients with ulcerative colitis and are presented in
tables 1 and 2.
Genotyping and SNP selection
A polymerase chain reaction – restriction fragment – length
polymorphism assay was used for genotyping three SNPs in the
NOD2 gene (R702W, G908R and 3020Cins). Full details on
primer sequences and assays are available on request. SNP
genotyping of all other polymorphisms was performed with
TaqMan probes and primers, using assays developed by Applied
Biosystems, and an ABI 7900HT system (Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands). A set of eight SNPs
was analysed for SLC22A4/5 and the IBD5 region. This set
included the two known risk-associated SNPs 1672 CRT
(rs1050152) and 2207GRC (rs2631367), and SNP rs3792876,
which was found to be associated with paediatric Crohn’s
disease in a cohort from the Academic Medical Center
Amsterdam.8 28 Three tag SNPs in the region were also analysed
(rs272893, rs273900 and rs274551). Two SNPs located at the 39
end (rs2522057) and 59 end (rs7705189) were chosen to analyse
linkage disequilibrium in the IBD5 region. Four SNPs were
analysed for DLG5 including the two risk-associated SNPs 113
GRA (R30Q, rs1248696) and 4136 CRA (P1371Q, rs2289310)
from the original paper by Stoll et al.9 Two more haplotype
Table 1 Clinical characteristics of patients with Crohn’s disease
Characteristic Number Per cent
Total number 1600
Sex (male/female) 568/1032 35.5–64.5
Age at diagnosis
,40 years 1335 83.4
.40 years 265 16.6
Disease localisation
Ileal 408 25.5
Colon 489 30.6
Ileocolon 703 43.9
Upper gastrointestinal tract* 190 11.9
Disease behaviour
Non-stricturing, non-penetrating 637 39.8
Stricturing 405 25.3
Penetrating 558 34.9
Perianal disease 433 27.1
Extra-intestinal manifestations 355 22.2
Operation 810 50.6
Family history of inflammatory bowel
disease
223 13.9
Mean follow-up (years) 14.2 (SD 10.4)
*Patients could be classified as having disease localisation in the upper
gastrointestinal tract next to ileal, colonic or ileocolonic localisation.
Table 2 Clinical characteristics of patients with ulcerative colitis
Characteristic Number Per cent
Total number 800
Sex (male/female) 430/370 53.8–46.2
Age at diagnosis
,40 years 575 71.9
.40 years 225 28.1
Disease localisation
Proctitis 130 16.3
Left-sided 304 38.0
Extensive 366 45.7
Extra-intestinal manifestations 106 13.3
Operation 130 16.3
Family history of inflammatory bowel
disease
103 12.9
Mean follow-up (years) 11.8 (SD 8.7)
Inflammatory bowel disease
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tagging SNPs were chosen to determine haplotype A
(rs2289311) and haplotype B (rs2165047). For IL23R, SNP
rs11209026 was analysed. The risk-associated SNP rs2241880
was determined for ATG16L1.11 Marker data for all these SNPs
are described in table 3.14
Statistical methods
As samples from seven centres were combined for analysis, we
first tested for homogeneity of the genotype data between
centres. Genotype frequencies were compared between the
centres using a x2 test separately for cases and controls. SNPs
rs272893, rs273900 and rs274551 in the control group of the
UMC Groningen and SNP rs2289311 in the cases from the
Academic Medical Center, Amsterdam, showed deviating
genotype frequencies (homogeneity p,0.05). For these SNPs
the groups concerned were discarded from further analyses.
Hardy–Weinberg equilibrium was tested among the unre-
lated, unaffected individuals using a x2 test with 1 degree of
freedom. SNP rs274551 in the control group of the UMC
Groningen showed deviation from Hardy–Weinberg equilibrium
(p,0.05) but had already been discarded from further analyses
because of genotypic heterogeneity.
The allele and genotype frequencies of patients and controls
were compared to test for association using the x2 test or
Fisher’s exact test where appropriate (SPSS 12.0.1). Since all five
genes had already been identified as associated genes for IBD,
Crohn’s disease and ulcerative colitis susceptibility, no multiple
testing correction was required. Thus, a multiple testing
correction was only performed in the genotype–phenotype
subgroup analyses for the number of complementary subgroups
of patients by using a Bonferroni correction. Linkage disequili-
brium and haplotype analyses were performed with in-house
software using an expectation maximisation algorithm. Linkage
disequilibrium parameters D9 and r2 were calculated for all pairs
of SNPs in the IBD5 region and in DLG5.
Odds ratios (ORs) and 95% confidence intervals (CIs) were
estimated using binary logistic regression (SPSS 12.0.1). Binary
logistic regression was also used to determine pairwise and three-
way, four-way and five-way gene–gene interaction effects with
inclusion of the main effects of each gene in the model. The main
Table 3 Marker data for genetic analysis of NOD2, IBD5, DLG5,
ATG16L1 and IL23R
Marker Comment
NOD2
rs2066844 R702W
rs2066845 G908R
3020insC
IBD5
rs7705189 59 end IBD5
rs3792876
rs272893
rs1050152 1672CRT
rs273900
rs2631367 2207GRC
rs274551
rs2522057 39 end IBD5
DLG5
rs2165047 Haplotype B
rs2289311 Haplotype A
rs2289310 Haplotype C; P1371Q
rs1248696 Haplotype D; R30Q
ATG16L1
rs2241880 T300A
IL23R
rs11209026 R381Q
ATG16L1, autophagy-related 16-like 1 gene; DLG5, Drosophila discs large homologue 5
gene; IBD5, inflammatory bowel disease 5 gene; IL23R, interleukin 23 receptor gene;
NOD2, nucleotide-binding and oligomerisation domain 2 gene.
Table 4 Allelic association analysis for NOD2, IBD5, DLG5, ATG16L1 and IL23R for patients with Crohn’s disease (n = 1684) or ulcerative colitis
(n = 1120) compared to healthy controls (n = 1350)
Locus
Controls Crohn’s disease Ulcerative colitis
MAF MAF p Value OR (95% CI) MAF p Value OR (95% CI)
NOD2
R702W 0.05 0.08 1.5661028 1.92 (1.53 to 2.42) 0.05 0.15 1.22 (0.93 to 1.60)
G908R 0.02 0.04 2.47610210 2.94 (2.07 to 4.18) 0.02 0.65 1.11 (0.71 to 1.73)
3020insC 0.02 0.07 3.58610217 3.26 (2.44 to 4.36) 0.02 0.91 1.02 (0.98 to 1.49)
IBD5
rs7705189 0.45 0.48 0.017 1.13 (1.02 to 1.26) 0.48 0.013 1.16 (1.03 to 1.30)
rs3792876 0.09 0.08 0.59 0.95 (0.79 to 1.15) 0.07 0.094 0.83 (0.67 to 1.03)
rs272893 0.37 0.36 0.24 0.94 (0.84 to 1.04) 0.35 0.13 0.91 (0.81 to 1.03)
rs1050152 0.41 0.45 0.015 1.14 (1.03 to 1.26) 0.44 0.036 1.13 (1.01 to 1.27)
rs273900 0.38 0.37 0.21 0.93 (0.84 to 1.04) 0.36 0.22 0.93 (0.82 to 1.05)
rs2631367 0.54 0.49 0.026 0.88 (0.79 to 0.99) 0.50 0.014 0.86 (0.77 to 0.97)
rs274551 0.17 0.15 0.039 0.86 (0.75 to 0.99) 0.17 0.48 0.95 (0.81 to 1.10)
rs2522057 0.40 0.45 5.0061024 1.20 (1.08 to 1.33) 0.44 2.72610203 1.19 (1.06 to 1.33)
DLG5
rs1248696 0.13 0.11 0.08 0.87 (0.74 to 1.02) 0.11 0.019 0.81 (0.68 to 0.97)
rs2289310 0.05 0.04 0.024 0.76 (0.59 to 0.97) 0.05 0.26 0.86 (0.66 to 1.12)
rs2289311 0.34 0.34 0.79 0.99 (0.88 to 1.10) 0.34 0.90 0.99 (0.88 to 1.12)
rs2165047 0.25 0.28 2.9061023 1.19 (1.06 to 0.92) 0.28 0.035 1.15 (1.01 to 1.30)
ATG16L1
rs2241880 0.44 0.39 3.6161024 0.82 (0.74 to 0.92) 0.45 0.42 1.05 (0.93 to 1.18)
IL23R
rs11209026 0.07 0.02 2.12610217 0.31 (0.23 to 0.41) 0.04 3.96610204 0.62 (0.48 to 0.81)
Values in bold type are statistically significant with a p value ,0.05.
ATG16L1, autophagy-related 16-like 1 gene; CI, confidence interval; DLG5, Drosophila discs large homologue 5 gene; IBD5, inflammatory bowel disease 5 gene; IL23R, interleukin 23
receptor gene; MAF, minor allele frequency; NOD2, nucleotide-binding and oligomerisation domain 2 gene; OR, odds ratio.
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effect was determined by the OR after logistic regression analysis
for the associated SNPs in each locus. In addition, ORs for Crohn’s
disease were calculated in a binary logistic regression analysis with
the number of risk alleles or risk genotypes at IBD5 rs2522027,
DLG5 rs2289310 and ATG16L1 rs2241880, IL23R rs11209026 and
carrying one of the three risk-associated polymorphisms in NOD2
(R702W, G908R and 1007fsinsC) as an independent variable. The
reference group consisted of all individuals with zero or one risk
allele or genotype. Ordinal regression analysis was used to test
whether patients with Crohn’s disease had more risk alleles than
controls. To further test whether the risk of being affected with
Crohn’s disease increases with increasing number of risk alleles,
we performed a x2 test for trend using the ratio of Crohn’s disease
cases versus controls within categories of number of risk alleles.
Since different genetic variants have differing effects on disease
susceptibility, a score was determined according to coefficients
calculated from separate logistic regression analyses for each SNP
associated with Crohn’s disease. In this way, the score was
weighted for the strength of association for each individual
genetic variant. Each patient was then categorised based on the
sum of these coefficients and ORs for each category were
determined by logistic regression analysis.
Besides disease occurrence we also looked at disease beha-
viour. For this purpose we again used the number of risk alleles
for IBD5 rs2522027, DLG5 rs2289310 and ATG16L1 rs2241880,
IL23R rs11209026 and carrying one of the three risk-associated
polymorphisms in NOD2 (R702W, G908R and 1007fsinsC). The
reference group consisted of all individuals with zero or one risk
allele or genotype. To analyse whether specific disease
behaviour of Crohn’s disease (early age of onset, familial
occurrence, stricturing and/or penetrating behaviour, perianal
disease, operation and extra-intestinal manifestations) was
associated with a higher number of risk alleles we performed
ordinal regression and trend analyses as described above. Since
disease behaviour can change over time we also performed these
analyses on patients with more than 5 years or more then
10 years of follow-up.
RESULTS
Association of NOD2, IBD5, DLG5, ATG16L1 and IL23R with IBD
Allelic association results for NOD2, IBD5, DLG5, ATG16L1,
and IL23R with Crohn’s disease and ulcerative colitis are
summarised in table 4.
NOD2
The polymorphisms R702W (p = 1.5661028; OR, 1.92; CI, 1.53
to 2.42), G908R (p = 2.4761028; OR, 2.77; CI, 1.92 to 4.01;) and
3020insC (p = 1.64610217; OR, 3.26; CI, 2.44 to 4.36) were all
strongly associated with Crohn’s disease, but did not show any
Table 5 Interaction analysis for NOD2, IBD5, DLG5, IL23R and ATG16L1
Interaction p Value OR (95% CI)
Two-way interaction
IBD5 6DLG5 0.67 0.86 (0.43 to 1.71)
IBD5 6 ATG16L1 0.58 1.15 (0.70 to 1.88)
IBD5 6NOD2 0.02 0.53 (0.31 to 0.92)
IBD5 6 IL23R 0.34 0.68 (0.31 to 1.51)
DLG5 6ATG16L1 0.77 0.88 (0.36 to 2.15)
DLG5 6NOD2 0.01 3.02 (1.29 to 7.08)
DLG5 6 IL23R 0.09 2.71 (0.85 to 8.62)
ATG16L1 6NOD2 0.06 0.51 (0.26 to 1.03)
ATG16L1 6 IL23R 0.74 0.85 (0.32 to 2.25)
NOD2 6 IL23R 0.77 1.15 (0.45 to 2.89)
Three-way interaction
IBD5 6DLG5 6 ATG16L1 0.72 1.08 (0.71 to 1.63)
IBD5 6DLG5 6NOD2 0.17 0.70 (0.42 to 1.17)
IBD5 6DLG5 6 IL23R 0.84 0.95 (0.56 to 1.60)
IBD5 6 ATG16L1 6NOD2 0.46 0.59 (0.35 to 0.99)
IBD5 6NOD2 6 IL23R 0.02 0.54 (0.32 to 0.92)
IBD5 6 ATG16L1 6 IL23R 0.69 0.92 (0.59 to 1.41)
DLG5 6ATG16L1 6NOD2 0.62 0.86 (0.48 to 1.55)
DLG5 6ATG16L1 6 IL23R 0.72 1.12 (0.60 to 2.10)
ATG16L1 6NOD2 6 IL23R 0.22 0.69 (0.38 to 1.25)
Four-way interaction
IBD5 6DLG5 6 ATG16L1 6NOD2 0.16 0.69 (0.41 to 1.15)
IBD5 6DLG5 6 ATG16L1 6 IL23R 0.83 1.04 (0.71 to 1.53)
IBD5 6DLG5 6NOD2 6 IL23R 0.22 0.73 (0.44 to 1.21)
IBD5 6 ATG16L1 6NOD2 6 IL23R 0.59 0.61 (0.36 to 1.02)
DLG5 6ATG16L1 6NOD2 6 IL23R 0.82 0.94 (0.54 to 1.62)
Five-way interaction
IBD5 6DLG5 6 ATG16L1 6NOD2 6 IL23R 0.74 0.74 (0.44 to 1.23)
Binary logistic regression analyses were performed using both main effects and interaction effects. The results of the interaction
effect are presented.
Values in bold type are statistically significant with a p value ,0.05.
The polymorphisms carried by the genes are: NOD2, carriage of one or more mutations for R702W, G908R or 3020insC; IBD5,
carriage of the rs2522027*C allele; ATG16L1, carriage of the rs2241880*G allele; DLG5, carriage of the rs2289310*C allele; IL23R,
carriage of the rs11209026*G allele.
ATG16L1, autophagy-related 16-like 1 gene; CI, confidence interval; DLG5, Drosophila discs large homologue 5 gene; IBD5,
inflammatory bowel disease 5 gene; IL23R, interleukin 23 receptor gene; NOD2, nucleotide-binding and oligomerisation domain 2
gene; OR, odds ratio.
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association with ulcerative colitis. The 3020insC polymorphism
was associated with ileal localisation (p = 2.3661025; OR, 1.83;
CI, 1.37 to 2.41), stricturing disease behaviour (p = 0.027; OR,
1.38; CI, 1.04 to 1.83) and the necessity of operation
(p = 1.7261024; OR, 1.69; CI, 1.28 to 2.23). The G908R
polymorphism was associated with stricturing behaviour
(p = 5.9161023; OR, 1.65; CI, 1.15 to 2.36).
IBD5
SNP rs1050152 (1672GRC) was associated with both Crohn’s
disease (p = 0.015; OR, 1.14; CI, 1.03 to 1.26) and ulcerative
colitis (p = 0.036; OR, 1.13; CI, 1.01 to 1.27). SNP rs2631367
(2207GRC) was also moderately associated with Crohn’s
disease (p = 0.036; OR, 0.88; CI, 0.79 to 0.99) and ulcerative
colitis (p = 0.011; OR, 0.86; CI, 0.77 to 0.97). The previously
described risk-associated TC haplotype for these two SNPs
combined was over-represented in Crohn’s disease (44.6%)
compared to controls (41.1%) (p = 0.0075; OR, 1.15 (1.04 to
1.28). However, the strongest association in the region was
observed for SNP rs2522057 at the 39 end of IBD5 with both
Crohn’s disease (p = 0.0005; OR, 1.20; CI, 1.08 to 1.33) and
ulcerative colitis (p = 0.0027; OR, 1.19; CI, 1.06 to 1.33). All
markers were in strong linkage disequilibrium. No specific
associations with the IBD5 locus were found for any subset of
patients with Crohn’s disease or ulcerative colitis.
DLG5
We observed an association of SNP rs2289310 (P1371Q, tagging
haplotype C) with Crohn’s disease (p = 0.024; OR, 0.76; CI, 0.59
to 0.97) but not with ulcerative colitis. The previously described
Crohn’s disease-associated SNP rs1248696 (R30Q) was not
associated with Crohn’s disease (p = 0.08) but showed moderate
association with ulcerative colitis in our cohort (p = 0.018; OR,
0.81; CI, 0.68 to 0.97). SNP rs2165047 was associated with both
Crohn’s disease (p = 0.0029; OR, 1.19; CI, 1.06 to 1.33) and
ulcerative colitis (p = 0.035; OR, 1.15; CI, 1.01 to 1.30) Although
SNP rs2289311 was not associated with Crohn’s disease
(p = 0.79) we did observe an association with the subgroup
with colonic disease localisation (p = 0.036; OR, 1.20; CI, 1.01
to 1.43). We did not find any gender specific associations of any
of the tested SNPs in DLG5.
ATG16L1
For the ATG16L1 rs2241880 SNP we observed an increased
frequency of the major allele G in Crohn’s disease cases (61%)
versus controls (56%) (p = 0.00036; OR, 1.22; CI, 1.09 to 1.35).
On subgroup analysis rs2241880 was associated with stricturing
behaviour (p = 0.005; OR, 1.27; CI, 1.07 to 1.50) and perianal
disease (p = 0.035; OR, 1.19; CI, 1.01 to 1.40).
IL23R
Carriers of allele A for SNP rs11209026 have a decreased risk for
developing Crohn’s disease (p = 2.12610217, OR, 0.31; CI, 0.23
to 0.40) and ulcerative colitis (p = 3.9661024; OR, 0.62; CI, 0.48
to 0.81).
Interaction of NOD2, IBD5, DLG5, ATG16L1 and IL23R for Crohn’s
disease susceptibility
Since the strongest associations are found with Crohn’s disease
and not with ulcerative colitis, we performed interaction
analysis only for patients with Crohn’s disease. For each
individual gene we selected the strongest associated genetic
variant for further analysis as described above. Interaction
analysis was performed for the following five associated risk
genotypes: NOD2 positive status (carrying one or more
mutations for R702W, G908R or 3020insC), carrying the
rs2522027*C allele for IBD5, carrying the rs2289310*C allele
for DLG5 and carrying the rs2241880*G allele for ATG16L1.
Since the allele rs11209026*A for IL23R has a protective effect
for Crohn’s disease, and hence the major allele G is associated
with an increased risk for Crohn’s disease, we used allele G for
the interaction analysis. Furthermore, since homozygosity for
the minor allele is very rare (0.2%), the risk ‘‘allele’’ for IL23R is
defined as homozygosity for rs11209026*G.
First, we evaluated whether there is a specific gene–gene
interaction. We performed two-way, three-way, four-way and
five-way gene–gene interaction analysis. This showed moderate
significant interaction between IBD5 and NOD2, DLG5 and
NOD2 and IBD5, NOD2 and IL23R. For all other combinations
this did not show any evidence for statistical interaction in
addition to the main effects of the individual genes, indicating
that each gene contributes independently to the susceptibility
to Crohn’s disease (table 5).
Next, we performed ordinal regression analysis which showed
that patients with Crohn’s disease carry more risk alleles (mean
4.41, SD 1.23) than controls (mean 3.84, SD 1.21); ordinal
regression analysis (p = 3.85610222). Binary logistic regression
analysis showed that individuals carrying an increasing number
of risk alleles were at increasing risk for Crohn’s disease
compared to controls carrying zero or one risk alleles (fig 1).
This reference group was chosen because none of the controls
carried zero risk alleles. We found that the OR for susceptibility
to Crohn’s disease increases with an increasing number of risk
alleles. Individuals with six risk alleles had an OR of 7.56 (CI,
2.78 to 20.57) for susceptibility to Crohn’s disease compared to
the reference group with zero or one risk allele. Individuals with
seven risk alleles had an OR of 25.6; however, since numbers in
Figure 1 Odds ratios (ORs) and confidence intervals (CIs) for patients
carrying increasing numbers of risk alleles for developing Crohn’s
disease. The risk alleles were: NOD2 – the presence of one of the
R702W, G908R or 3020insC polymorphisms was defined as one risk
allele; IBD5 – the rs2522027*C allele; ATG16L1 – the rs2241880*G
allele; DLG5 – the rs2289310*C allele; the risk ‘‘allele’’ for IL23R is
defined as homozygosity for rs11209026*G. The reference group
consists of individuals with zero or one risk allele. The progressive
increase in ORs is consistent with an independent effects multiplicative
model. ATG16L1, autophagy-related 16-like 1 gene; DLG5, Drosophila
discs large homologue 5 gene; IBD5, inflammatory bowel disease 5
gene; IL23R, interleukin 23 receptor gene; NOD2, nucleotide-binding and
oligomerisation domain 2 gene.
Inflammatory bowel disease
392 Gut 2009;58:388–395. doi:10.1136/gut.2007.144865
 group.bmj.com on August 16, 2011 - Published by gut.bmj.comDownloaded from 
this group are becoming small (n = 60), the CI is large (6.80 to
96.46). There were too few patients with eight or nine risk
alleles to justify further statistical analysis. Trend analysis
revealed a highly significant progressive increase in ORs with
increasing number of risk alleles (ptrend = p = 4.25610223). In
fig 2 we show that this effect was also seen with an increasing
number of risk genotypes (ptrend = 2.37610227). Since different
genetic variants have differing effects on disease susceptibility,
we performed the same analysis using a weighted score based on
the coefficients calculated from separate logistic regression
analyses for each SNP associated with Crohn’s disease, as
explained in the methods section. A similar progressive increase
in ORs for an increasing weighted score is seen (fig 3).
We then tested whether an increasing number of risk alleles
was associated with a more severe disease course. For 1353
patients with Crohn’s disease we had complete genotypes for all
associated genes and complete phenotypic descriptions. First we
found that patients with Crohn’s disease with a more severe
disease course, defined as penetrating or stricturing disease
behaviour, had significantly more risk alleles compared to
patients with non-stricturing, non-penetrating behaviour (ordi-
nal regression, p = 0.001; ptrend = 0.0008). Similarly, patients
who needed surgical intervention had significantly more risk
alleles compared to those without operations (ordinal regres-
sion, p = 0.03; ptrend = 0.02). Patients with an age of onset
below 40 years had more risk alleles then patients with an age
of onset above 40 years (ordinal regression, p = 0.048;
ptrend = 0.028). There was no association for the number of risk
alleles and the occurrence of perianal disease or extra-intestinal
manifestations. Since phenotypes can change over time we then
performed these analyses on the groups of patients with
Crohn’s disease with complete genotyping data available and
with more than 5 years (n = 1072) and more than 10 years
(n = 763) of follow-up. It has to be emphasised that these
groups partly overlap. These results are depicted in table 6.
Although it would be expected that the group with more than
10 years of follow-up is enriched with patients with compli-
cated disease behaviour, we could not find any association with
worse disease behaviour in this particular group. This is
probably due to a lack of power in this specific subset.
DISCUSSION
We have looked at the combined impact of five genetic variants
that show association with susceptibility to Crohn’s disease in
the Dutch IBD population and shown that the relative risk for
Crohn’s disease increases with an increasing number of risk
alleles, consistent with an independent effects multiplicative
model. We also showed that an increasing number of risk alleles
is associated with a more severe disease course and a younger
age of onset.
It is essential that genetic associations found for IBD are
confirmed in large, independent cohorts.29 We first corroborated
the association with NOD2 and then confirmed the association
of the IBD5 haplotype with Crohn’s disease. Although the
previously described ‘‘TC haplotype’’ in SLC22A4/5 was over-
represented in patients with IBD compared to controls in our
study, this effect was not independent of the IBD5 haplotype.8
We did find an association for DLG5 with IBD. However, this
association was not with the R30Q variant but with the
rs2289310 (P1371Q) and rs2165047 (‘‘haplotype B’’) SNPs.9 10
The latter SNP was also associated with ulcerative colitis, which
is a novel finding. This indicates that DLG5 might be a (modest)
risk factor for both phenotypes of IBDs.9 We were also able to
confirm the association of the recently identified ATG16L1 gene
with Crohn’s disease. On a phenotypic level we found it to be
associated with Crohn’s disease with stricturing disease
behaviour and and perianal disease. Although a recent report
found a low but significant risk for ulcerative colitis, we did not
find an association for ATG16L1 with ulcerative colitis or any
specific subsets of ulcerative colitis.30 IL23R SNP rs11209026
(R381Q) was strongly associated with a protective effect for
Crohn’s disease in our cohort. We also found a significant but
Figure 2 Odds ratios (ORs) and confidence intervals (CIs) for patients
carrying increasing numbers of genotypes for developing Crohn’s
disease. The genotypes are NOD2 (carrying R702W, G908R or
3020insC), IBD5 (carrying the rs2522027*C allele), DLG5 (carrying the
rs2289310*C allele), ATG16L1 (carrying the rs2241880*G allele) and
IL23R (carrying the rs11209026*G allele). The reference group consists
of individuals with zero or one risk genotype. ATG16L1, autophagy-
related 16-like 1 gene; DLG5, Drosophila discs large homologue 5 gene;
IBD5, inflammatory bowel disease 5 gene; IL23R, interleukin 23 receptor
gene; NOD2, nucleotide-binding and oligomerisation domain 2 gene.
Figure 3 Odds ratios (ORs) and confidence intervals (CIs) for a
combined risk score based on the relative weight for each Crohn’s
disease risk allele. The coefficient score for the Crohn’s disease risk
alleles was determined by logistic regression analysis. Each patient was
categorised based on the sum of these coefficients. The risk alleles were
NOD2 – the presence of one of the R702W, G908R or 3020insC
polymorphisms; IBD5 – the rs2522027*C allele; ATG16L1– the
rs2241880*G allele; DLG5 – the rs2289310*C allele; the risk ‘‘allele’’ for
IL23R is defined as homozygosity for rs11209026*G. ATG16L1,
autophagy-related 16-like 1 gene; DLG5, Drosophila discs large
homologue 5 gene; IBD5, inflammatory bowel disease 5 gene; IL23R,
interleukin 23 receptor gene; NOD2, nucleotide-binding and
oligomerisation domain 2 gene.
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less pronounced protective effect in ulcerative colitis patients.
This is consistent with recent reports.13–15
We demonstrated that it is possible to combine information
from multiple common low-penetrance variants to predict the
susceptibility for a complex disease like Crohn’s disease. Our
findings are consistent with the idea that multiple genes, each
with a small overall contribution, are involved in the suscept-
ibility to Crohn’s disease. For NOD2 we used the polymorph-
isms associated with Crohn’s disease combined with the most
strongly associated SNPs for the IBD5 locus, DLG5, ATG16L1
and IL23R, for our interaction analysis. These genes (with the
exception of NOD2) have low ORs (,1.5) for the risk of
developing Crohn’s disease and are therefore, independently, of
limited use in predicting the risk for disease development.
However, although there is very little specific gene–gene
interaction, combining the information from these common
risk alleles increases the predictive value for developing Crohn’s
disease. There is a significant progressive increase in the OR for
Crohn’s disease with each added risk allele. Individuals carrying
six risk alleles had an OR of 7.56 compared to individuals
carrying zero or one risk allele. Since different genetic variants
have differing effects on disease susceptibility, the same analysis
was performed using categories based on the sum of the
weighted scores for each risk allele. The same progressive
increase in ORs is observed. Furthermore, since the effect size of
the NOD2 gene might be a dominant factor in the analysis, we
performed the same analysis without including data of NOD2.
Similarly, since DLG5 is less replicated than the other Crohn’s
disease susceptibility genes, we performed the same analysis
without including DLG5. The same significant increase in ORs
consistent with an independent effects multiplicative model
was observed in both instances (data not shown). In a recent
meta-analysis of three genome-wide association scans that have
been performed more than 30 distinct susceptibility loci have
been identified. When performing additional gene–gene inter-
action analysis, no strong evidence of deviation from this model
of multiplicative effects was found in this large study.31
The absolute difference in the number of risk alleles between
patients with Crohn’s disease and controls is, although highly
statistically significant, moderate. This is due to the fact that
some of the identified Crohn’s disease susceptibility variants,
like ATG16L1, are common variants with high prevalences in
the healthy population. In combination with the low prevalence
of Crohn’s disease in the population this obviously limits the
predictive value for an individual for disease development.2 Very
recently, a number of genome-wide association studies have
identified several more genetic associations with Crohn’s
disease.16–18 It can be anticipated that, once these associations
are confirmed, they will further increase the risk for developing
Crohn’s disease. On the other hand, it can also be hypothesised
that there will be no further increase in disease risk, but a
plateau phase will be reached. In our total group of 4154
individuals studied, only six carried eight risk alleles. Five of
them were patients with Crohn’s disease and one was a healthy
control. Therefore, since the numbers of individuals with more
risk alleles will be even smaller, much larger cohorts than ours
will be needed to analyse this.
An increasing number of risk alleles is not only associated
with the susceptibility to Crohn’s disease but also with a more
severe course of the disease. It is associated with an age of onset
,40 years, fibrostenotic or fistulising disease behaviour and the
need for surgical intervention. We did not find any associations
for the number of risk alleles with perianal disease or extra-
intestinal manifestations. Since disease phenotypes can change
over time it can be expected that the patient group with a long-
term follow-up would be enriched with patients with complica-
tions like fibrostenotic disease and surgery. We therefore
analysed patients with a follow-up of more then 5 years and
more than 10 years separately for disease behaviour. We found
an association with stricturing and/or penetrating behaviour
and familial occurrence in the patients with a follow-up of more
than 5 years. However, all associations were lost when we
analysed patients with a follow-up of more than 10 years. This
could be due to a lack of power in this specific subset. We show
that molecular testing can help to identify specific subgroups.
Since Crohn’s disease is a chronic disorder with an unpredictable
disease course, it is important for clinicians to identify these
patients, since they might benefit from early intervention and a
more aggressive treatment of Crohn’s disease. On the other
hand, patients with a favourable prognosis can be spared the
side effects of unnecessary treatment. In the future, it might be
possible to classify patients with Crohn’s disease based on their
genetic background in combination with other factors such as
circulating antibodies, and environmental factors such as
smoking. This will allow clinicians to identify patient groups
and to adjust their treatment. Obviously, large population-
based prospective studies will be needed to establish this.
In conclusion, we have shown that if we combine informa-
tion from the risk-associated genetic variants for NOD2, IBD5,
DLG5, ATG16L1 and IL23R, the relative risk for developing
Crohn’s disease increases with an increasing number of risk
alleles or genotypes, consistent with an independent effects
multiplicative model. An increase in the number of risk alleles is
also associated with a more severe disease course. These findings
Table 6 Results of ordinal regression analysis for the number of risk alleles associated with Crohn’s disease,
depicting whether an increasing number of risk alleles is associated with specific disease characteristics
Characteristic All (n = 1353) Follow-up .5 years (n = 1072)
Follow-up .10 years
n = 763
Age at diagnosis ,40 years 0.048 0.06 0.58
Familial occurrence 0.12 0.03 0.69
Stricturing and/or penetrating behaviour 0.001 0.006 0.052
Perianal disease 0.57 0.60 0.67
Operation 0.03 0.07 0.13
Extra-intestinal manifestations 0.17 0.42 0.85
Values in bold type are statistically significant with a p value ,0.05.
The risk alleles were: NOD2, the presence of one of the R702W, G908R or 3020insC polymorphisms was defined as one risk allele;
IBD5, the rs2522027*C allele; ATG16L1, the rs2241880*G allele; DLG5, the rs2289310*C allele; the risk ‘‘allele’’ for IL23R is defined
as homozygosity for rs11209026*G.
ATG16L1, autophagy-related 16-like 1 gene; DLG5, Drosophila discs large homologue 5 gene; IBD5, inflammatory bowel disease 5
gene; IL23R, interleukin 23 receptor gene; NOD2, nucleotide-binding and oligomerisation domain 2 gene.
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emphasise that it might be possible to create a genetic risk
profile to predict the disease course for a patient with Crohn’s
disease and to adjust their treatment accordingly.
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